BOLT - Bolt Biotherapeutics, Inc.
Previous close
0.5165
0.005 1.065%
Share volume: 300
Last Updated: Fri 27 Dec 2024 05:55:11 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.51
0.01
1.08%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-10 | 2022-11-10 | 2023-03-29 | 2023-05-11 | 2023-08-07 | 2023-11-09 | 2024-03-21 | 2024-05-14 | |
| Assets | |||||||||
| Total Assets | 260.237 M | 245.505 M | 227.807 M | 206.181 M | 190.696 M | 175.355 M | 159.784 M | 142.892 M | |
| Current Assets | 181.262 M | 174.826 M | 172.746 M | 131.609 M | 130.668 M | 125.466 M | 105.708 M | 95.055 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 4.927 M | 3.696 M | 3.858 M | 5.230 M | 4.802 M | 5.742 M | 3.519 M | 3.705 M | |
| Short Term Investments | 4.927 M | 3.696 M | 3.858 M | 5.230 M | 4.802 M | 5.742 M | 3.519 M | 3.705 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 176.335 M | 171.130 M | 168.888 M | 126.379 M | 125.866 M | 119.724 M | 102.189 M | 91.350 M | |
| Total Non-current Assets | 78.975 M | 70.679 M | 55.061 M | 74.572 M | 60.028 M | 49.889 M | 54.076 M | 47.837 M | |
| Property Plant Equipment | 6.525 M | 6.905 M | 6.453 M | 6.035 M | 5.609 M | 5.266 M | 4.957 M | 4.499 M | |
| Other Assets | 23.604 M | 23.777 M | 23.100 M | 22.386 M | 21.634 M | 21.220 M | 20.941 M | 20.112 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 260.237 M | 245.505 M | 227.807 M | 206.181 M | 190.696 M | 175.355 M | 159.784 M | 142.892 M | |
| Total liabilities | 52.269 M | 57.059 M | 56.301 M | 48.495 M | 48.564 M | 47.096 M | 47.043 M | 38.733 M | |
| Total current liabilities | 18.622 M | 24.174 M | 23.118 M | 16.253 M | 17.618 M | 18.751 M | 20.456 M | 16.723 M | |
| Accounts Payable | 3.362 M | 3.828 M | 3.594 M | 1.835 M | 3.436 M | 3.682 M | 2.987 M | 2.219 M | |
| Other liabilities | 12.898 M | 12.028 M | 12.963 M | 12.674 M | 12.055 M | 10.168 M | 9.150 M | 5.330 M | |
| Current long term debt | 2.145 M | 2.384 M | 2.391 M | 2.484 M | 2.581 M | 2.680 M | 2.782 M | 2.887 M | |
| Long term debt | 20.749 M | 20.857 M | 20.220 M | 19.568 M | 18.891 M | 18.177 M | 17.437 M | 16.680 M | |
| Other liabilities | 12.898 M | 12.028 M | 12.963 M | 12.674 M | 12.055 M | 10.168 M | 9.150 M | 5.330 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 207.968 M | 188.446 M | 171.506 M | 157.686 M | 142.132 M | 128.259 M | 112.741 M | 104.159 M | |
| Common stock | 37.294 M | 37.454 M | 37.558 M | 37.684 M | 37.750 M | 37.868 M | 37.945 M | 38.068 M | |
| Retained earnings | -253.332 M | -275.091 M | -295.088 M | -312.068 M | -330.125 M | -346.382 M | -364.285 M | -375.096 M |